valsartan has been researched along with Cardiac Diseases in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Huynh, K | 1 |
| Ge, T; Yang, Y; Zhao, Y | 1 |
| El Nozahi, M; Rezq, A; Saad, M | 1 |
| Chandrabhatla, AS; Christiansen, SL; Holmes, JW; Nelson, AR; Saucerman, JJ; Zeigler, AC | 1 |
| Abdel Fattah, SM; Ibrahim, DM; Radwan, RR | 1 |
| Dai, M; Qian, D; Tao, H; Zhang, C | 1 |
| Arya, DS; Bharti, S; Goyal, S; Sahoo, KC; Sharma, AK | 1 |
| Bozcali, E; Dedeoglu, DB; Karpuz, H; Karpuz, V; Suzer, O | 1 |
| Cohn, JN; Duprez, DA; Florea, ND; Jones, K | 1 |
| Coca, A; Giner, V | 1 |
| Corvol, P; Plouin, PF | 1 |
2 review(s) available for valsartan and Cardiac Diseases
| Article | Year |
|---|---|
[Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Heart Diseases; Heart Failure; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 1999 |
[Angiotensin II receptor blockers: current status and future prospects].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Diseases; Humans; Hypertension; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2002 |
4 trial(s) available for valsartan and Cardiac Diseases
| Article | Year |
|---|---|
A study of the efficacy of sacubitril/valsartan plus dapagliflozin combination treatment in pulmonary arterial hypertension due to left heart disease.
Topics: Heart Diseases; Heart Failure; Humans; Pulmonary Arterial Hypertension; Stroke Volume; Valsartan; Ventricular Function, Left | 2023 |
Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.
Topics: Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Diseases; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Ramipril; ST Elevation Myocardial Infarction; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2021 |
Clinical efficacy and ultrasound inspection of the treatment of hypertensive heart patients with Valsartan combined with hydrochlorothiazide.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Echocardiography; Female; Heart Diseases; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Treatment Outcome; Valsartan; Ventricular Function, Left | 2018 |
Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Comorbidity; Coronary Artery Disease; Disease Progression; Double-Blind Method; Exercise Test; Female; Fluorescein Angiography; Health Status Indicators; Heart Diseases; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Pilot Projects; Predictive Value of Tests; Tetrazoles; Valine; Valsartan | 2007 |
5 other study(ies) available for valsartan and Cardiac Diseases
| Article | Year |
|---|---|
Valsartan attenuates cardiac dysfunction and remodelling in patients with HCM.
Topics: Aminobutyrates; Heart Diseases; Humans; Stroke Volume; Valsartan | 2021 |
Network model-based screen for FDA-approved drugs affecting cardiac fibrosis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Arsenic Trioxide; Biphenyl Compounds; Computer Simulation; Drug Combinations; Fibroblasts; Fibrosis; Heart Diseases; Humans; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Models, Animal; Network Pharmacology; Pyrazoles; Quaternary Ammonium Compounds; Quinolines; Rats; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad3 Protein; Thioctic Acid; Valsartan | 2021 |
Antioxidant and antiapoptotic effects of sea cucumber and valsartan against doxorubicin-induced cardiotoxicity in rats: The role of low dose gamma irradiation.
Topics: Animals; Antioxidants; Apoptosis; Aspartate Aminotransferases; Caspase 3; Creatine Kinase; Doxorubicin; Gamma Rays; Glutathione; Heart Diseases; Male; Myocardium; Nitric Oxide Synthase Type II; Oxidative Stress; Peroxidase; Rats; Reactive Oxygen Species; Sea Cucumbers; Troponin I; Valsartan | 2017 |
Valsartan, an angiotensin II receptor blocker, attenuates cardiac dysfunction and oxidative stress in isoproterenol-induced cardiotoxicity.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Cardiotonic Agents; Cardiotoxins; Heart Diseases; Heart Rate; Isoproterenol; Male; Oxidative Stress; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2011 |
Cardioprotective effects of zofenopril, enalapril and valsartan against ischaemia/reperfusion injury as well as doxorubicin cardiotoxicity.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Doxorubicin; Enalapril; Heart Diseases; Hemodynamics; Humans; Male; Rats; Rats, Wistar; Reperfusion Injury; Tetrazoles; Valine; Valsartan | 2012 |